BGPT: Paper Review: Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer

Fuel Your Discoveries

Quick Explanation Copied

Core finding (with scientific skepticism)

In a single-center retrospective cohort of 108 papillary thyroid cancer (PTC) patients, the authors report that overweight-range BMI (X-tile cutoff 24.3 kg/m²) is associated with higher odds of BRAF V600E (OR 7.645, 95% CI 1.275–45.831, p = 0.026), with the association appearing stronger/persisting in females.

Skeptical takeaway: this is hypothesis-generating due to cohort size, retrospective design, possible BMI measurement bias, and lack of public mutation-level/raw data availability in the text you provided.

Long Explanation

Paper Review: Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer

Citation: 10.1007/s13277-015-4718-y (Tumor Biology; received 27 Oct 2015, accepted 21 Dec 2015; published online per metadata you provided).

1) Study question & key result (what they claim)

The study asks whether BMI is associated with BRAF V600E mutation status in papillary thyroid cancer (PTC), and whether an overweight-range BMI cutoff predicts mutation probability.

Reported primary quantitative finding

In multivariate logistic regression, BMI categorized as ≥24.3 kg/m² (vs <24.3 kg/m²) is associated with BRAF V600E (OR 7.645, 95% CI 1.275–45.831, p = 0.026).

Reported effect heterogeneity

The authors report the BMI–BRAF association persists in females (with a BMI-associated OR reported for females) but not in males.

2) Visualizations from the provided raw numbers

Graphs below use only counts explicitly present in the manuscript text you provided (e.g., mutation counts by Hashimoto’s thyroiditis status and sex).

Male: 17/28; Female: 34/80 reported in the sex × mutation table you provided.

HT positive: 9/42 (21.4%); HT negative: 42/66 (63.6%) as stated in the results.

Multivariate OR for BMI category reported as 7.645 (95% CI 1.275–45.831).

3) Methods audit (is the measurement pipeline coherent?)

3.1 Cohort design, eligibility, and sample size

The manuscript describes reviewing 104 consecutive PTC patients (2012–2014) at one center, with further mutation-screening reported for 108 PTC patients in the provided text.

Exclusion criteria include prior thyroid disease/cancer history, other health conditions/medications, and diabetes, intended to reduce influences on BMI.

The provided baseline table reports 108 patients, mean age 43.9 ± 12.5, 28 males and 80 females, and mean BMI 22.97 ± 2.89 kg/m².

3.2 Genotyping / mutation calling

BRAF V600E was analyzed from tissue DNA using PCR (primers explicitly listed) followed by sequencing on an ABI Genetic Analyzer, and mutation positivity was defined using a threshold on the second peak (>50% second peak).

Mutation prevalence in the cohort is reported as 51/108 (47.2%) BRAF positive.

3.3 BMI measurement and threshold selection

BMI is defined as weight (kg) divided by height (m) squared, and the BMI cutoff is identified by X-tile to predict mutation by overweight.

The cutoff value is reported as 24.3 kg/m², described as near the midpoint between upper-normal BMI and WHO overweight threshold in the discussion.

4) Statistical analysis review (what is strong vs fragile)

Univariate/multivariate logistic regression is used to estimate odds ratios for BRAF V600E according to BMI (continuous and dichotomized) and clinicopathologic variables.
Cutoff selection risk: using X-tile to find an “optimal” cutoff can inflate apparent significance if not validated externally; the manuscript describes an X-tile approach but the provided excerpt does not show independent external replication.
Effect size uncertainty: BMI OR is large (7.645) but has a very wide CI (1.275–45.831), consistent with modest sample size and/or sparsity after categorization.
Potential residual confounding: variables included as covariates may not fully capture BMI-related biological pathways (e.g., insulin resistance, adipokines, etc.); the authors explicitly discuss possible intermediates but does not measure them in the provided text.

5) Blind spots & falsifiability checkpoints (what could change the conclusion)

5.1 Measurement bias & selection effects

The authors mention a limitation that participants were asked to recall body weight and height at diagnosis, and they argue this could bias BMI downward (self-reported BMI typically lower than measured BMI), potentially impacting observed associations.

The cohort is heavily female (74.1%), so sex-specific findings require caution; the authors themselves note sample size limitations for gender stratification.

Single-center retrospective sampling can introduce selection bias in the included patients and in tissue availability for genotyping; the provided text does not include an external replication cohort or data deposition.

5.2 Correlation vs causation

Because BMI and mutation are assessed at/around diagnosis in a retrospective cohort, the design supports association, not causation; any causal story would require longitudinal BMI measures preceding tumorigenesis and/or mechanistic work.

6) Mechanistic plausibility (what the authors suggest vs what’s untested here)

The manuscript proposes plausible intermediates between overweight BMI and BRAF V600E status, including TSH elevation, insulin resistance, and adipokines, but notes that underlying mechanisms remain unclear and require further investigation.

7) What I would demand to be convinced (scientific checklist)

External replication: independent cohort with prespecified BMI categories (or pre-registered cutoff) showing the same direction and magnitude of association.
Better BMI measurement: measured BMI prior to diagnosis (or long before tumor detection) to reduce recall bias.
Mediation/biology bridge: direct measurement of candidate intermediates (TSH dynamics, insulin resistance markers, adipokines) and testing whether they mediate BMI → BRAF V600E association.
Analytic robustness: sensitivity analyses (e.g., different BMI cut points, alternative modeling for sex) and reporting of full model outputs/diagnostics (not shown in the excerpt you provided).

8) Author & conflict-of-interest transparency (from provided text)

The provided metadata you included states the authors declare no competing interests, and the funding sources are listed in the article header.

9) Bespoke BGPT follow-ups (author-centered)

Feedback:

Updated: April 26, 2026